AMLX (STOCKS)
Amylyx Pharmaceuticals, Inc. Common Stock
$15.190000
+0.600000 (+4.11%)
Prev close: $14.590000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joshua B. Cohen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,690.03M
- Employees
- 123
- P/E (TTM)
- -9.68
- P/B (TTM)
- 5.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.37 | $-0.34 | -0.0331 | -9.82% |
|
Dec 2025 (Q4)
|
$-0.30 | $-0.37 | +0.0660 | +18.03% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.46 | +0.0889 | +19.37% |
|
Jun 2025 (Q2)
|
$-0.46 | $-0.45 | -0.0060 | -1.32% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $159.27M |
| Nonoperating Income/Loss | $9.20M |
| Selling, General, and Administrative Expenses | $63.37M |
| Research and Development | $95.90M |
| Operating Income/Loss | -$159.27M |
| Income/Loss From Continuing Operations After Tax | -$150.11M |
| Income/Loss From Continuing Operations Before Tax | -$150.07M |
| Net Income/Loss | -$150.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$150.11M |
| Net Income/Loss Available To Common Stockholders, Basic | -$150.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.48 |
| Diluted Earnings Per Share | -$1.48 |
| Basic Average Shares | 298,182,920 |
| Diluted Average Shares | 298,182,920 |
| Assets | $293.60M |
| Current Assets | $285.02M |
| Noncurrent Assets | $8.58M |
| Fixed Assets | $212.00K |
| Other Non-current Assets | $8.37M |
| Liabilities | $20.44M |
| Current Liabilities | $15.97M |
| Accounts Payable | $3.53M |
| Wages | $3.20M |
| Other Current Liabilities | $9.24M |
| Noncurrent Liabilities | $4.48M |
| Equity | $273.16M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $273.16M |
| Liabilities And Equity | $293.60M |
| Net Cash Flow From Operating Activities | -$120.40M |
| Net Cash Flow From Operating Activities, Continuing | -$120.40M |
| Net Cash Flow From Investing Activities | $93.96M |
| Net Cash Flow From Investing Activities, Continuing | $93.96M |
| Net Cash Flow From Financing Activities | $194.58M |
| Net Cash Flow From Financing Activities, Continuing | $194.58M |
| Exchange Gains/Losses | $766.00K |
| Net Cash Flow | $168.91M |
| Net Cash Flow, Continuing | $168.14M |
| Comprehensive Income/Loss | -$150.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$149.87M |
| Other Comprehensive Income/Loss | -$34.70M |
| Other Comprehensive Income/Loss Attributable To Parent | $241.00K |